TransMedics Group, Inc. (TMDX) Free cash flow 2018–2025
TransMedics Group, Inc. (TMDX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$133.6MFY2025 · since FY2018: -$26.4M → $133.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $133.6M | +265.0% |
| FY2024 | -$80.9M | +50.9% |
| FY2023 | -$164.9M | -185.6% |
| FY2022 | -$57.7M | -78.3% |
| FY2021 | -$32.4M | -5.4% |
| FY2020 | -$30.7M | +5.3% |
| FY2019 | -$32.5M | -22.9% |
| FY2018 | -$26.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More TMDX financial trends
TMDX RevenueTMDX Net incomeTMDX Net marginTMDX Gross profitTMDX Gross marginTMDX Operating incomeTMDX Operating marginTMDX Operating cash flowTMDX Capital expendituresTMDX Return on equityTMDX Stock buybacksTMDX Dividends paidTMDX Total assetsTMDX Total liabilitiesTMDX Shareholders’ equityTMDX overview →